Search research articles
Contact Us
Filters
Showing results (191-200 of 380) with videos related to
Page
of 38
Sort By:
Nature Communications
|
April 21, 2026
Cell fate specification during respiratory development requires ARID1A-containing canonical BAF complex activity
Hyunwook Lee, Abigail Jaquish, Sharlene Fernandes, et al.
ESMO Open
|
June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
U Dafni, R A Soo, S Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2020
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
V A Papadimitrakopoulou, T S Mok, J-Y Han, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma
H R Kim, H N Kang, H S Shim, et al.
ESMO Open
|
May 4, 2023
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
G Galffy, I Lugowska, E V Poddubskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2019
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
R S Herbst, P Baas, J L Perez-Gracia, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
R A Soo, K Vervita, M Früh, et al.
Journal of Viral Hepatitis
|
April 17, 2018
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients
S H Yoo, J H Kwon, S W Nam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics
|
January 3, 2023
[Status of fungal sepsis among preterm infants in 25 neonatal intensive care units of tertiary hospitals in China]
X C Cao, S Y Jiang, S J Li, et al.
Page
of 38
Search research articles
Search
Showing results (191-200 of 380) with videos related to
Sort By:
Page
of 38
Nature Communications
|
April 21, 2026
Cell fate specification during respiratory development requires ARID1A-containing canonical BAF complex activity
Hyunwook Lee, Abigail Jaquish, Sharlene Fernandes, et al.
ESMO Open
|
June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
U Dafni, R A Soo, S Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2020
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
V A Papadimitrakopoulou, T S Mok, J-Y Han, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma
H R Kim, H N Kang, H S Shim, et al.
ESMO Open
|
May 4, 2023
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
G Galffy, I Lugowska, E V Poddubskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2019
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
R S Herbst, P Baas, J L Perez-Gracia, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
R A Soo, K Vervita, M Früh, et al.
Journal of Viral Hepatitis
|
April 17, 2018
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients
S H Yoo, J H Kwon, S W Nam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics
|
January 3, 2023
[Status of fungal sepsis among preterm infants in 25 neonatal intensive care units of tertiary hospitals in China]
X C Cao, S Y Jiang, S J Li, et al.
Page
of 38